SARS-CoV-2 virus either five or 13 weeks after the second injection were protected from viral replication in the lungs and nose, the researchers said.Mice challenged seven weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung, they said.NIAID Vaccine Research Center (VRC) scientists worked with investigators from the University of Texas at Austin to identify the atomic structure of the spike protein on the surface of the novel coronavirus.This structure was used by Moderna in the development of the vaccine candidate, according to the researchers.The latest study found that the investigational vaccine also induced robust CD8 T-cell responses in mice.It did not induce the type.